s
TO THE MEMBERS,
The Directors have pleasure in presenting before you the THIRTY NINE Annual
Report of SANDU PHARMACEUTICALS LIMITED together with Audited Balance Sheet and
Statement of Profit & Loss for the financial year ended 31st March, 2024.
1. FINANCIAL RESULTS:-
The Company's financial performance, for the year ended March 31, 2024 is summarized
below:
(in Lakhs)
|
Standalone |
Consolidated |
Particulars |
2023-24 |
2022-23 |
2023-24 |
2022-23 |
Revenue from Operations (Gross) |
6,728.07 |
6534.90 |
6,728.07 |
6534.90 |
Other Income |
42.13 |
32.72 |
42.36 |
32.72 |
Total Income |
6,770.20 |
6567.62 |
6,770.43 |
6567.62 |
Total Expenses |
6,562.97 |
6,345.61 |
6,563.14 |
6345.95 |
Profit/(loss) before exceptional items and tax |
207.24 |
222.00 |
207.39 |
221.67 |
Exceptional Items / Prior Period Adjustment |
0.00 |
0 |
0.00 |
0 |
Profit/Loss Before Tax |
207.24 |
222.01 |
207.29 |
221.67 |
Tax Expenses |
|
|
|
|
Current Tax |
58.71 |
62.85 |
58.71 |
62.85 |
Deferred Tax |
2.46 |
3.38 |
2.46 |
3.42 |
Short/(excess) tax provision |
0.00 |
3.39 |
0.00 |
3.39 |
Total Tax Expenses |
61.18 |
69.62 |
61.17 |
69.66 |
Profit/(Loss) for the Period |
146.06 |
152.39 |
146.12 |
152.01 |
Total Other Comprehensive Income (Net of Tax) |
61.79 |
56.96 |
61.49 |
56.96 |
Total Comprehensive Income for the period (Net of Tax) |
207.55 |
209.35 |
207.61 |
208.98 |
Earnings per equity shares |
|
|
|
|
Basic |
1.51 |
1.62 |
1.510 |
1.99 |
Diluted |
1.51 |
1.62 |
1.510 |
1.87 |
2. REVIEW OF OPERATIONS (in lakhs)
Standalone
In the financial year 2023-24, the company achieved an Income from operations of Rs.
6,728.07 as compared to Rs. 6,534.90 in the previous year.
Profit before tax was Rs. 207.24 for the year ending 31st March, 2024 as compared to
Profit of Rs. 222.01 in the previous year.
Profit after tax was Rs. 146.06 for the year ended 31st March, 2024 as compared to a
Profit of Rs. 152.39 in the previous year.
Consolidated
In the financial year 2023-24, the company achieved an Income from operations of Rs.
6,728.07 as compared to Rs. 6,534.90 in the previous year.
Profit before tax was Rs. 207.29 for the year ending 31st March, 2024 as compared to
Profit of Rs. 221.67 in the previous year.
Profit after tax was Rs. 146.12 for the year ended 31st March, 2024 as compared to a
Profit of Rs. 152.01 in the previous year.
There were no material changes and commitments affecting the financial position of the
Company from the end of the financial year till the date of the Directors Report.
3. SUBSIDIARY COMPANY
As on 31st March 2024, your Company had only 01 unlisted wholly owned subsidiary named
Sandu Phytoceuticals Private Limited. In accordance with the provisions of Regulation
16(1)(C) of the Listing Regulations pertaining to the threshold for determining Material
Subsidiary of the Company, there was no Material Subsidiary of the Company during the
financial year.
In accordance with Section 136 of the Companies Act 2013,The audited financials
statements, including consolidated financials statements will be available on our website
www.sandu.in. The Company would provide the Annual Accounts of the Subsidiaries and the
related detailed information to the Shareholders of the Company on specific request made
to it in this regard .The same will also be available at the Registered Office of the
Company for inspection during the office hours.
The financial statements of the Company are prepared in accordance with Section 129(3)
of the Companies Act, 2013. Further, a statement containing salient features of the
financial statements of our subsidiaries in prescribed format AOC-1 is appended as
Annexure I.
The statement also provides the details of performance and financial position of each
subsidiary.
The Board of Directors at its Meeting held on 30th May 2024 has approved sale of 100 %
investment in its wholly owned Subsidiary in favour of Shri Umesh Sandu and Shri Shashank
Sandu. The consideration amount payable has been arrived based on valuation report issued
by CA Murli Chandak, IBBI Registered valuer of Securities and financial assets. The
process of sale of investment has already been inititated ,Once completed Sandu
Phytoceuticals Private Limited shall cease to be Subsidiary of Sandu Pharmaceuticals
Limited.
Sandu Phytoceuticals Private Limited is unlisted / Not Material Subsidiary to Sandu
Pharmaceuticals Limited but still Company has formulated Policy on Material Subsidiary and
has been uploaded on Companys Website at https://sandu.in/wp-content/
uploads/2023/07/POLICY-FOR-DETERMINING- MATERIAL-SUBSIDIARIES.pdf
4. DECLARATION AND PAYMENT OF DIVIDEND
The Company has a track record of rewarding its shareholders. An Final dividend of Rs.
0.80 paisee per equity share (i.e 8% on the paid up capital) for the FY 2023-24 has been
recommended by Board of Directors subject to approval of Shareholders. This recommendation
is a reflection of the Company's improved financial performance and its commitment to
enhancing shareholder value.
5. SHARE CAPITAL:
As on 31st March 2024, the authorised, issued, subscribed and paid-up Share Capital is
as follows :
Authorised Capital |
Rs. 10,00,00,000 (Ten Crore Only) |
Issued, Subscribed and Paid-up Share Capital |
Rs. 9,66,09,900 (Nine Crore Sixty Six Lakhs Nine Thousand and Nine Hundred Only) |
6. DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND
BANKRUPTCY CODE, 2016
During the year, no applications have been made and no proceedings are pending against
the Company under the Insolvency and Bankruptcy Code, 2016.
7. RISK MANAGEMENT:
The Board has laid down a clear Risk Management Policy to identify potential business
risks and install effective mitigation processes to protect Company's assets and business
Risks. Risk Management Policy and the details of this policy are available on the website
of the Company under the web link https:// sandu.in/image/catalog/info-pages/Announcement/
policies/Risk-Management-Policy.pdf
8. INTERNAL FINANCIAL CONTROL SYSTEMS AND THEIR ADEQUACY:
The Company has adequate Internal Financial Control Systems, commensurate with the
size, scale and complexity of its operations. The Management evaluates the efficacy and
adequacy of internal control system in the Company, its compliance with operating systems,
accounting procedures and policies of the Company on an ongoing basis.
9. VIGIL MECHANISM / WHISTLE BLOWER POLICY:
Pursuant to Section 177(9) of the Companies Act, 2013 read with Rule 7 of the Companies
(Meetings of Board and its Powers) Rules, 2014 and Regulation 22 of SEBI (Listing
Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors had
approved the Policy on Whistle Blower. This Policy inter-alia provides a direct access to
the Chairman of the Audit Committee.
Your Company hereby affirms that no Director/ employee have been denied access to the
Chairman of the Audit Committee and that no complaints were received during the year.
Whistleblower Policy approved and adopted by the Board of Directors which can be accessed
in our website https://sandu.in/image/ catalog/info-pages/Announcement/policies/Whistle-
Blower-Policy.pdf
9.1 BOARD EVALUATION
Pursuant to the provisions of the Companies Act, 2013 and SEBI (Listing Obligations and
Disclosure Requirements) Regulations 2015 the Board has carried out an annual evaluation
of its own performance, the Directors individually as well as the evaluation of the
working of its Audit, Nomination & Remuneration and Stakeholders Relationship
Committee. The manner in which the evaluation has been carried out has been given in the
Corporate Governance Report. The Weblink of familiarization Programme undertaken for
Independent Director is also available https://sandu.
in/wp-content/uploads/2024/03/Familarisation- programme-for-Independent-Director.pdf
The Nomination and Remuneration Committee has defined the evaluation criteria and
procedure for the Performance Evaluation process for the Board, its Committees and
Directors. The criteria for Board Evaluation include inter alia, Board structure and
composition, establishment and delineation of responsibilities to various Committees,
effectiveness of Board processes, information and functioning.
Criteria for evaluation of individual Directors include aspects such as attendance and
contribution at Board/ Committee Meetings and guidance/ support to the Management outside
Board/ Committee Meetings. In addition, the Chairman was also evaluated on key aspects of
his role, including setting the strategic agenda of the Board, encouraging active
engagement by all Board Members and motivating and providing guidance to the Managing
Director/Executive Director.
Criteria for evaluation of the Committees of the Board include degree of fulfillment of
key responsibilities, adequacy of Committee composition and effectiveness of meetings.
9.2 NOMINATION AND REMUNERATION POLICY
The policy of the Company on Directors Appointment and Remuneration, including criteria
for determining qualifications, positive attributes, independence of a Director and other
matter, as required under sub section (3) of Section 178 of the Companies Act, 2013 is
available on our website https://sandu.in/ image/catalog/info-pages/Announcement/policies/
Nomination-and-Remuneration-Policy.pdf. There has been no change in the policy since the
last fiscal year. We affirm that the remuneration paid to the Directors is as per the
terms laid out in the Nomination and Remuneration Policy of the Company.
9.3 MEETINGS
During the year 05 (five) Board Meetings and 05 (Five) Audit Committee Meetings were
convened and held. The details of which are given in the Corporate Governance Report. The
intervening gap between the Meetings was within the period prescribed under the Companies
Act 2013.
9.4 AUDIT COMMITTEE
The details of the Composition of the Audit Committee are given in the Corporate
Governance Report. During the year all the recommendations of the Audit Committee were
accepted by the Board.
9.5 POLICIES
We seek to promote and follow the highest level of ethical standards in all our
business transactions guided by our value system. The SEBI (Listing Obligation and
Disclosure Requirements) Regulations, 2015 mandated the formulation of certain policies
for all Listed companies. All our Corporate Governance policies are available on our
website www.sandu. in.The policies are reviewed periodically by the Board and updated
based on need and new compliance requirement.
10. DIRECTORS AND KEY MANAGERIAL PERSONNEL:-
(a) Key Managerial Personnel.
Shi Umesh Sandu-Managing Director, Shri Rakesh Parekh-Chief Financial Officer upto 31st
December 2023,Smt Pratika Mhambray- Company Secretary have been designated as Key
Managerial Personnel in accordance with the provisions of Section 203 of the Companies Act
2013.
Shri Vijay Kajarekar has been appointed as Chief Financial Officer with effect from
30th March 2024 pursuant to resignation of Shri Rakesh Parekh.
(b) Appointment and Reappointment of Directors
In accordance with the provision of the Act and Articles of Association of the Company,
Shri Shashank B Sandu Non Executive Director of the Company retires by rotation and being
eligible offers himself for reappointment .A resolution seeking members approval for his
reappointment forms part of the Notice Shashank B Sandu holding DIN:00678098 (Non
Executive Director) retires by rotation and, being eligible offer himself for Re
appointment.
The Board of Directors on recommendation of Nomination and Remuneration Committee and
in accordance with Article of Association and Securities and Exchange Board of India
(LODR) 2015 has appointed Shri Vijay Kottapalli (DIN: 10245156) as Additional Non
Executive Director at its meeting held on12th August 2024 for the term of 05 years w.e.f
12th August 2024 and who have given declarations that they meet the criteria of
independence as laid down under section 149(6) of the Companies Act, 2013.Resolution
seeking Shareholders approval is mentioned in the Notice of the Annual General Meeting.
On recommendation of the Nomination and Remuneration Committee ,the Board of Directors
has proposed candidature of Smt Jayshree Sandu (DIN:07480177) as Non Executive Non
Independent Director aged above 75 years in respect of which company has also received
notice in writing under Section 160 proposing her candidature with effect from 30th
September 2024 subjected to approval of Shareholders in the forthcoming AGM.
During the year under review, the Non Executive Directors of the Company had no
pecuniary relationship or transactions with the Company.
(c) Declaration by Independent Director
Pursuant to sub section (7) of Section 149 of the Companies Act 2013 read with rules
made thereunder, all the Independent Directors of the Company have given the declaration
that they meet criteria of Independence as laid down in subsection (6) of Section 149 of
the Act and Regulation 16(1)(b) of the SEBI (Listing Obligation and Disclosure
Requirements) Regulation 2015.
(d) Retirement of Independent Director
The 02nd term of 05 years Tenure of the below mentioned Independent Directors was over
on the closure of Business hour i.e 31st March 2024. The Board of Directors placed on
record its appreciation for the Exemplary and outstanding contribution made bt outgoing
Directors.
A. Shri Vinay Kumar Kottapalli (DIN:02322747) Non Executive Independent Director and
Chairman.
B. Shri Dilip Salgaocar (DIN:00044240) Non Executive Independent Director.
C. Shri Dr Madan Kapre (DIN:03113515) Non Executive Independent Director.
D. Shri Dr Krishna Deshpande (DIN:06557518) Non Executive Independent Director.
In addition to its Code of Conduct and Ethics, key policies that have been adopted by
the Company are as follows:
Name of the Policy |
Brief Description |
Web link |
Whistleblower Policy |
The Company has adopted the whistleblower mechanism for Directors and Employees to
report concerns about unethical behavior, actual or suspected frauds, or violation of the
Company's code of conduct and ethics. There has been no change to the Whistleblower Policy
adopted by the Company during the fiscal 2016 |
https://sandu.in/image/catalog/ info-pages/Announcement/
policies/Whistle-Blower-Policy.pdf |
Nomination and Remuneration Policy |
This policy formulates the criteria for determining qualifications, competencies,
positive attributes and independence for the appointment of a Director (Executive/ Non
Executive) and also the criteria for determining the remuneration of the Directors, Key
Managerial Personnel and other employees. |
https://sandu.in/image/catalog/ info-pages/Announcement/ policies/Nomination-and-
Remuneration-Policy.pdf |
Related Party Transaction Policy |
The policy regulates all transactions between the Company and its related parties |
https://www.sandu.in/ image/catalog/info-pages/ Announcement/policies/Policy_
on_Materiality_and_%20Dealing_ with_Relate d_Party_Transaction s. pdf |
Insider Trading Policy |
The Policy provides framework in dealing with securities of the Company |
https://sandu.in/image/catalog/ info-pages/Announcement/
policies/Insider-Trading-Policy.pdf |
Policy for determining Materiality of event or Information |
This Policy for Determination of Materiality of Events or Information is aimed at
providing guidelines to the Management of Sandu Pharmaceuticals Limited, to determine the
materiality of events or information, which could affect investment decisions and ensure
timely and adequate dissemination of information to the Stock Exchange(s) (as hereinafter
defined). |
https://sandu.in/wp-content/ uploads/2023/08/POLICY-ON- DISCLOSURE-OF-MATERIAL-
EVENTS-INFORMATION.pdf |
Archival Policy |
The Policy deals archival of corporate records of Sandu Pharmaceuticals Limited |
https://sandu.in/image/catalog/ info-pages/Announcement/ policies/Archival_Policy.pdf |
Board Diversity Policy |
This policy aims to set out the approach to achieve diversity on the Board of
Directors ("Board") of Sandu Pharmaceuticals Limited |
https://sandu.in/image/catalog/ info-pages/Announcement/ p
olicies/Policy-on-Board-Diversity. pdf |
Risk Management Policy |
The Risk management policy of Sandu Pharmaceuticals Limited will enable the Company to
proactively manage uncertainty and changes in the internal and external environment to
limit negative impacts and capitalize on opportunities. |
https://sandu.in/image/catalog/ info-pages/Announcement/
policies/Risk-Management-Policy. pdf |
Material Subsidiary Policy |
The Policy for determining Material' Subsidiaries (hereinafter referred as
"the/this Policy") has been framed in accordance with the requirements of the
Regulation 16 (1) (c) of SEBI (Listing Obligations and Disclosure Requirements)
Regulations, 2015 (hereinafter referred to as "the Listing Regulations"). |
https://sandu.in/wp-content/ uploads/2023/07/POLICY-FOR- DETERMINING-MATERIAL-
SUBSIDIARIES.pdf |
11. DIRECTORS RESPONSIBILITY STATEMENT:-
In accordance with the provisions of section 134(3) (c) read with section 134(5) of the
Companies Act 2013, your Directors confirm that:
a) In the preparation of annual accounts, for the year ended 31st March 2024, the
applicable accounting standards read with the requirements set out under Schedule III to
the Act, have been followed and there are no material departures from the same.
b) Appropriate accounting policies have been selected and applied consistently and
judgments and estimates made are reasonable and prudent so as to give a true and fair view
of the state of affairs of the Company as on 31st March, 2024 and of the profit of the
Company for the year ended on that date.
c) Proper and sufficient care has been taken for the maintenance of adequate accounting
records in accordance with the provisions of the Act for safeguarding the assets of the
Company and for preventing and detecting fraud and other irregularities.
d) The annual accounts have been prepared on a 'Going Concern Basis'.
e) Internal financial controls to be followed by the Company have been laid down and
that such internal financial controls are adequate and are operating effectively
f) Proper systems have been devised to ensure compliance with the provisions of all
applicable laws and that such systems are adequate and operating effectively.
12. CORPORATE SOCIAL RESPONSIBILTY POLICY:
Section 135 of the Companies Act, 2013 relating to Corporate Social Responsibility is
not applicable and hence the Company need not adopt any Corporate Social Responsibility
Policy.
13. THE AMOUNT IF ANY WHICH IT PROPOSES TO CARRY TO ANY RESERVE
The Company has not transferred any amount to Reserve and hence it is NIL.
14 RELATED PARTY TRANSACTIONS:
The Related Party Contracts entered into between Related Parties, does not fall under
the ambit of Section 188(1) of the Act.
All the Related Party Transactions entered during the financial year were at arm's
length and in the ordinary course of business. In compliance with the provisions of the
Companies Act 2013 and Regulation 23(2) of the SEBI Regulation 2015, all Related Party
Transactions had been placed before the Audit Committee for prior approval. Pursuant to
Section 134(3)(h) of the Act read with Rule 8(2) of the Companies (Accounts) Rules, 2014
information pertaining to Related Parties are given in Form AOC-2 as Annexure I of this
Report.
15. SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS
There were no significant material orders passed by the Regulators/Courts which could
impact the going concern status of the Company and its future operations.
16. AUDITORS
16.1 STATUTORY AUDITORS
M/s Dileep and Prithvi, are the Statutory Auditor of the Company appointed for the term
of 5 years i.e for the Financial Year 2021-2026 as recommended by Members of Audit
Committee /Board of Directors and subsequently approved by the Members at the 36th Annual
General Meeting.
Based on the recommendation of Audit Committee, Board of Directors at its Meeting held
on 12th August 2024 has proposed to increased remuneration payable to Statutory Auditor
for the Financial Year 2024-25 and 2025-26 subjected to approval of Shareholders in the
forthcoming Annual General Meeting.
16.2 SECRETARIAL AUDITOR:
Pursuant to provisions of section 204 of the Companies Act, 2013 and the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014 the company has
appointed Shri. Swapnil Dixit, Company Secretary in practice to undertake the Secretarial
Audit of the Company for the Financial Year 2023-24. The Secretarial Audit report for the
financial year 2023-24 is annexed herewith as "ANNEXURE B".
16.3 INTERNAL COMPLAINTS COMMITTEE
As per provisions of Section 4 of the Sexual Harassment of Women at Workplace
(Prevention, Prohibition and Redressal) Act, 2013, your Company has constituted an
Internal Complaints Committee for Redressal of complaints against sexual harassment and
there were no complaints received during the financial year.
16.4 DISCLOSURE REQUIREMENTS
Your Company has complied with all the mandatory requirements of SEBI (Listing
Obligations and Disclosure Requirements) Regulations 2015.
Management Discussion and Analysis is annexed as "ANNEXURE A"
to the report
Secretarial Audit Report as "ANNEXURE B".
As per SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015
with the Stock Exchanges, a separate section on the corporate governance is annexed as
"Annexure C"
Auditors Certificate on Corporate Governance "Annexure D"
Certificate from Chief Financial Officer under Regulation 17(8) of SEBI (LODR)
Regulation "Annexure E",
Declaration from Managing Director "Annexure F"
Certificate of Non Disqualification of Director "Annexure G"
17. CONSERVATION OF ENERGY, RESEARCH AND DEVELOPMENT, TECHNOLOGY ABSORPTION,
FOREIGN EXCHANGE EARNINGS AND OUTGO.
A) CONSERVATION OF ENERGY:
a) Company ensures that the manufacturing operations are conducted in the manner
whereby optimum utilization and maximum possible savings of energy is achieved.
b) No specific investment has been made in reduction in energy consumption.
c) As the impact of measures taken for conservation and optimum utilization of energy
are not quantitative, its impact on cost cannot be stated accurately.
d) The required data with regard to conservation of energy as applicable to our company
is furnished below:
Particulars |
For the year ended 31.03.2024 |
For the year ended 31.03.2023 |
1. ELECTRICITY |
|
|
Purchased (units) |
3,12,416 |
2,96,924 |
Total Amount ' |
26,78,665 |
26,01,373 |
Rate/Units in ' |
8.57 |
8.76 |
FUEL CONSUMED |
|
|
Quantity-Furnace Oil |
47970 |
38.84 |
LDO |
0 |
24000 |
Diesel |
3826 |
4570 |
Total amount- Furnace Oil |
29,84,402 |
17,94,966 |
LDO |
0 |
20,88,480 |
Diesel |
3,45,049 |
4,12,976 |
Rate per Ltr- Furnace Oil |
62.21 |
46214.37 |
LDO |
0.00 |
87.02 |
Diesel |
90.19 |
90.37 |
B) TECHNOLOGY ABSORPTION:
Company's products are manufactured by using in-house know how and no outside
technology is being used for manufacturing activities. Therefore no technology absorption
is required. The Company constantly strives for maintenance and improvement in quality of
its products and entire Research & Development activities are directed to achieve the
aforesaid goal.
C) FOREIGN EXCHANGE EARNINGS AND OUTGO:
During the period under review there was no foreign exchange earnings or out flow.
18. EXTRACT OF ANNUAL RETURN
As provided under section 92 (3) ofthe Act, the extract of the Annual Return in form
MGT- 9 is annexed herewith as "Annexure H" which forms part of this report.
As per the requirement of Section 92 of the Companies Act 2013, read with Rule 12 of
the Companies (Management & Administrative) Rule, 2014 .The Annual Return in the
prescribed form is available on the Companies Site www.sandu.in
19. STATEMENT OF PARTICULARS OF APPOINTMENT AND REMUNERATION OF MANAGERIAL PERSONNEL
The information required under section 197 of the Act read with Rule 5 of The Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of employees
of the Company and Directors is annexed as "Annexure - H" to this report.
20. FIXED DEPOSITS:-
Your Company has not accepted any deposits from public within the meaning of Section 73
of the Companies Act, 2013 and the Companies (Acceptance of Deposits from Public) Rules
2014 during the financial year 2023-24.
21. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS:-
The Company has not given any loans or guarantees covered under the provisions of
section 186 of the Companies Act, 2013.The details of the Investments made by the Company
are given in the notes to the financial statements.
22. PARTICULARS OF CONTRACT OR ARRANGMENTS WITH RELATED PARTY
The Company has Related Party Transaction with Sandu Brother Private Limited which is
in ordinary course of Business and on Arm Length Basis duly approved by the Members.
23. CODE OF CONDUCT:
The Board of Directors has approved a Code of Conduct which is applicable to the
Members of the Board and all employees in the course of day to day business operations of
the company. The Code of Conduct for Directors https://sandu.in/image/
catalog/info-pages/Announcement/policies/Code-of- Conduct-for-Senior-Management.pdf has
been posted on companies Website.
The Code lays down the standard procedure of business conduct which is expected to be
followed by the Directors and the designated employees in their business dealings and in
particular on matters relating to integrity in the work place, in business practices and
in dealing with stakeholders.
All the designated employees and personnel have confirmed compliance with the Code. The
Declaration signed by the Managing Director pursuant to Regulation 26(3) read with
Schedule V (Part D) of the SEBI (LODR) Regulation 2015 is published in this report.
24. PREVENTION OF INSIDER TRADING:
The Company has adopted a Code of Conduct for Prohibition of Insider Trading with a
view to regulate trading in securities by the Directors and Designated employees of the
Company. The Code requires preclearance for dealing in the Company's shares and prohibits
the purchase or sale of Company shares by the Directors and the designated employees while
in possession of unpublished price sensitive information in relation to the Company and
during the period when the Trading Window is closed. The Board is responsible for
implementation of the Code.
Code of Conduct for Prohibition of Insider Trading is available on website of the
Company under the web link https://sandu.in/image/catalog/info-pages/
Announcement/policies/Insider-Trading-Policy.pdf
The Company has in place a Structured Digital Database wherein details of persons with
whom UPSI is shared on need to know basis and for legitimate business purposes is
maintained with time stamping and audit trails to ensure non-tampering of the database.
The Structured Digital Database is maintained internally by the Company and is not
outsourced in accordance with the provisions of the SEBI Insider Trading Regulations.
25. PARTICULARS OF EMPLOYEES:
The information required pursuant to Section 197 read with rule 5 of the Companies
(Appointment and Remuneration of Managerial Personnel) Rules, 2014 in respect of employees
of the Company, will be provided upon request. In terms of Section 136 of the Act, the
reports and accounts are being sent to the members and others entitled thereto, excluding
the information on employees' particulars which is available for inspection by the members
at the Registered office of the company during business hours on working days of the
company up to the date of ensuing Annual General Meeting. If any member is interested in
inspecting the same, such member may write to the company secretary in advance.
26. AUDITORS REPORT AND SECRETARIAL AUDIT REPORT
The Statutory Audit Report and Secretarial Audit Report doesn't contain any
qualification, reservation or adverse remarks.
27 . ONE TIME SETTLEMENT
Details of difference between amount of the valuation done at the time of one time
settlement and the valuation done while taking loan from the Banks or Financial
Institutions along with the reasons thereof NOT APPLICABLE
28. REPORTING OF FRAUDS
There Have Been No Instances Of Fraud Reported By The Auditors Under Section 143(12) Of
The Act And Rules Framed Thereunder Either To The Company Or To The Central Government.
29. ACKNOWLEDGEMENTS:
Your Company and its Directors wish to extend their sincerest thanks to the Members of
the Company, Bankers, State Government, Local Bodies, Customers, Suppliers, Executives,
Staff and workers at all levels for their continuous cooperation and assistance.
For and on behalf of Board of Directors |
|
of Sandu Pharmaceuticals Limited |
|
Sd/- |
Sd/- |
Umesh B Sandu |
Shashank B Sandu |
DIN:01132141 |
DIN:00678098 |
Managing Director |
Director |
Dated: 12/08/2024 |
|
Place: Mumbai |
|